HGH 176-191 Peptide is a 16-amino acid fragment corresponding to residues 176-191 at the C-terminus of human growth hormone (hGH), also known as the "lipolytic fragment." It exhibits significant fat breakdown-promoting and fat synthesis-inhibiting effects, without the growth-promoting or glucose metabolism-interfering side effects associated with full-length hGH. Currently, it is primarily used in scientific research related to obesity and metabolism. Composed of the 16 amino acids from the C-terminus of hGH, its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a molecular weight of approximately 1817.1 g/mol and a molecular formula of C₇₈H₁₂₅N₂₃O₂₃S₂. HGH Fragment 176-191 Peptide (hereinafter referred to as peptide 176-191) demonstrates multifaceted biological effects in the fields of bone metabolism regulation, articular cartilage repair, and joint protection. Its core actions revolve around maintaining bone remodeling balance, protecting chondrocyte homeostasis, regulating the synthesis-degradation balance of the cartilage matrix, and repairing the joint microenvironment. Moreover, its mechanism of action is characterized by tissue specificity and physiological gentleness.
Our product overview
HGH 176-191 COA
I. Bidirectional Regulation of Bone Metabolism: Maintaining the Physiological Balance of Bone Remodeling
The core of bone metabolism lies in the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Peptide 176-191 can optimize the rhythm of bone remodeling and enhance the structural and functional stability of bone tissue by regulating the functions of these two core cell types:
Promoting Osteoblast Proliferation and Functional Activation
In vitro cell experiments have confirmed that peptide 176-191 can directly act on osteoblast precursor cells, accelerating their differentiation into mature osteoblasts.
It upregulates the expression of key functional markers in osteoblasts-including osteocalcin, type I collagen, and alkaline phosphatase-which are crucial components for bone matrix synthesis and mineralization.
This peptide can activate relevant signaling pathways within osteoblasts, enhancing their ability to form mineralized nodules, thereby directly boosting the efficiency of bone matrix synthesis and mineralization, and aiding in bone tissue construction and repair.
Moderately Inhibiting Osteoclast Activity to Reduce Excessive Bone Resorption
Excessive osteoclast activation is a central cause of bone loss and deterioration of bone microarchitecture. Peptide 176-191 can regulate osteoclast differentiation signals, inhibiting the conversion of osteoclast precursors into mature osteoclasts.
It also reduces the bone-resorbing function of mature osteoclasts (e.g., their ability to form resorption pits).
Its inhibitory effect is physiologically moderate; it does not excessively block the normal physiological process of bone resorption but merely corrects abnormally heightened resorption.This helps maintain the physiological "bone formation - bone resorption" balance, reduces abnormal bone loss, and improves bone density and the integrity of trabecular bone structure.
Optimizing the Bone Tissue Microenvironment to Aid Bone Repair
This peptide can modulate the secretion of local cytokines in bone tissue, promoting the gentle expression of growth factors related to bone repair.
It improves the nutrient supply and cell survival microenvironment of bone tissue. Particularly in scenarios of bone injury or micro-fracture repair.
It can accelerate the recruitment of osteoblasts to the damaged area and the deposition of bone matrix.This shortens the bone repair cycle and enhances the mechanical strength of the repaired bone tissue.
II. Core Repair and Protective Effects on Articular Cartilage (Key Focus)
Articular cartilage is the core functional structure of joints, composed of chondrocytes and extracellular matrix (primarily type II collagen and proteoglycans). Its damage and degeneration are central causes of joint dysfunction. The effects of peptide 176-191 on articular cartilage span the entire chain of "chondrocyte protection - matrix synthesis - degradation inhibition - microenvironment repair," which is the core manifestation of its joint-protective value:
Protecting Chondrocyte Survival and Inhibiting Apoptosis
Chondrocyte apoptosis is the initiating step in cartilage degeneration. Peptide 176-191 can inhibit apoptosis-related signaling pathways within chondrocytes.It reduces chondrocyte apoptosis induced by factors such as oxidative stress and inflammatory stimuli, while enhancing the stress resistance of chondrocytes, thereby maintaining the homeostasis of chondrocyte number and activity.In vitro experiments show that this peptide can significantly reduce the apoptosis rate of chondrocytes in injury models, safeguarding the cellular foundation of cartilage tissue.
Promoting Synthesis of Chondrocyte Extracellular Matrix and Repairing Cartilage Structure
The elasticity and compressive resistance of articular cartilage depend on the intact composition of type II collagen and proteoglycans. Peptide 176-191 can directly activate the matrix-synthesizing function of chondrocytes.
On one hand, it upregulates the gene expression and protein synthesis of type II collagen and aggrecan, increasing the content of core cartilage matrix components.On the other hand, it promotes the synthesis and deposition of glycosaminoglycans (GAGs) within the matrix, enhancing the hydration capacity and mechanical properties of cartilage. This reverses the degenerative loss of cartilage matrix and repairs its microstructure.
Matrix metalloproteinases (MMPs, e.g., MMP-1, MMP-3, MMP-13) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS, e.g., ADAMTS-4, ADAMTS-5) are key enzymes that degrade cartilage matrix. Their abnormally high expression is a central driver of cartilage degeneration.Peptide 176-191 can significantly downregulate the expression and activity of these degrading enzymes, reducing the enzymatic breakdown of type II collagen and proteoglycans.By blocking the "degradation end," it interrupts the continuous damage to cartilage. Combined with its promotion of matrix synthesis, this creates a bidirectional "synthesis-degradation" regulation, achieving steady-state repair of cartilage.
Modulating the Joint Microenvironment and Reducing Inflammation-Mediated Cartilage Damage
Chronic low-grade inflammation within joints is a significant trigger for cartilage degeneration. Peptide 176-191 can inhibit the abnormal secretion of local inflammatory factors in joints (such as IL-1β and TNF-α).
It reduces the damaging stimulation of chondrocytes by inflammatory factors. Simultaneously, it decreases inflammatory infiltration and hyperplasia in the synovial membrane, thereby reducing the indirect damage to cartilage caused by degrading enzymes and inflammatory mediators released by inflamed synovium.
This optimizes the physiological microenvironment within the joint, creating stable conditions for cartilage repair.
III. Potential Intervention Effects in Joint Diseases and Cartilage Injury
Based on the aforementioned regulatory effects on bone and cartilage, peptide 176-191 demonstrates potential intervention value in various joint-related pathological scenarios, with a core focus on diseases associated with cartilage degeneration and joint structural damage:
Osteoarthritis is characterized by progressive degeneration of articular cartilage, osteophyte formation, and synovial inflammation.
Animal studies show that intervention with peptide 176-191 can significantly reduce the severity of articular cartilage damage in OA models. It diminishes cartilage surface ulceration, fibrosis, and matrix loss, while maintaining cartilage thickness and integrity.Simultaneously, it inhibits abnormal osteophyte proliferation, lowers synovial inflammation scores, improves joint mechanical function and range of motion, and delays OA pathological progression.
Auxiliary Repair of Articular Cartilage Defects
For focal articular cartilage defects caused by trauma or degeneration, peptide 176-191 can promote the recruitment and proliferation of chondrocytes in the defect area.It accelerates cartilage matrix deposition at the defect site, reducing fibrotic scar repair (fibrocartilage replacement) in the area.
This increases the proportion of hyaline cartilage and improves the mechanical properties of the repaired cartilage, aiding in the functional repair of cartilage defects and lowering the risk of progression to full-thickness cartilage damage.
Repair of Combined Bone-Cartilage Injuries
For complex joint injuries involving both bone micro-damage and cartilage degeneration, peptide 176-191 can exert a dual effect: promoting bone formation while protecting and repairing cartilage.It helps repair damaged bone tissue, restoring structural stability at the bone-cartilage interface, while simultaneously protecting articular cartilage and halting degenerative progression.
This enables synergistic repair of the joint's bone and cartilage structures, enhancing the overall functional recovery of the joint.
IV. Core Characteristics of the Mechanism of Action: Gentle Modulation and Low Perturbation
Peptide 176-191's action in the bone and joint field possesses unique advantages, distinguishing it from full-length growth hormone and certain potent bone metabolism modulators:
Its regulation of bone formation and cartilage synthesis involves physiological activation, devoid of overstimulation effects.
It does not cause pathological changes such as abnormal bone tissue hyperplasia or excessive cartilage hypertrophy. It primarily corrects abnormal bone and cartilage metabolic imbalances, restoring physiological homeostasis.
Tissue Targeting:
Its effects are focused on bone cells, chondrocytes, and the joint microenvironment.
It has no direct intervention effects on other tissues and organs throughout the body, avoiding functional perturbation of non-target tissues and ensuring high precision of action.
Low Risk of Side Effects
It does not bind to the growth hormone receptor, eliminating concerns associated with full-length growth hormone, such as potential issues of excessive bone growth or abnormal joint enlargement.
This suggests a higher potential safety profile for interventions aimed at bone and cartilage repair.
Currently, research on peptide 176-191 in the fields of bone metabolism and articular cartilage repair primarily remains at the stage of *in vitro* cell experiments and animal disease models. Core findings are focused on its roles in regulating bone remodeling balance, protecting chondrocytes and the extracellular matrix, and delaying joint degeneration. However, through its bidirectional and balanced regulation of bone metabolism, comprehensive chain of repair and protection for articular cartilage, and optimization of the joint microenvironment, it demonstrates significant scientific value in scenarios such as bone metabolic disorders, articular cartilage degeneration, and joint injury repair. Its gentle and precise mode of action offers a new direction for mechanistic research on joint cartilage-related diseases and the exploration of intervention strategies.
Hot Tags: HGH 176-191 Peptide, China HGH 176-191 Peptide manufacturers, suppliers, Tirzepatide Oral Drops, hgh fragment 176 191 peptide, Semaglutide Gummies, AOD 9604 Powder, AOD 9604 Injection, ghrp 6 tablets
